Hexyl aminolevulinate fluorescence cystoscopy in bladder cancer

Expert Review of Anticancer Therapy

Volumn 9, Issue 8, 2009, Pages 1055-1063

  Sievert, Karl Dietrich ^a   Kruck, Stephan ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

5 Aminolevluinic acid; 5 Aminolevulinate acid; Bladder cancer; Diagnosis; Fluorescence cystoscopy; Hexyl aminolevulinate; Photodynamic diagnostic tool; Recurrence free survival; Sensitivity; Specificity; Transurethral resection of bladder tumor; Treatment

Indexed keywords

AMINOLEVULINIC ACID HEXYL ESTER; BCG VACCINE; MITOMYCIN C; MONOCLONAL ANTIBODY;

ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CLINICAL TRIAL; CYSTOSCOPY; EARLY DIAGNOSIS; EUROPE; FLUORESCENCE IMAGING; HUMAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRECANCER; SENSITIVITY AND SPECIFICITY; UNITED STATES; WHITE LIGHT ENDOSCOPY;

AMINOLEVULINIC ACID; CLINICAL TRIALS AS TOPIC; CYSTOSCOPY; FLUORESCENT DYES; HUMANS; NEOPLASM RECURRENCE, LOCAL; PRACTICE GUIDELINES AS TOPIC; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS;

EID: 70350686585     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.73     Document Type: Article

References (66)

1. Felknor SA, Delclos GL. Occupational Risk Factors. In: Textbook of Bladder Cancer. Lerner SP, Schoenberg M, Sternberg CN (Eds). Taylor & Francis, Oxon, UK 19-26 (2006).
2. Yu MC, Skipper PL, Tannenbaum SR, Chan KK, Ross RK. Arylamine exposures and bladder cancer risk. Mutat. Res. 506-507, 21-28 (2002).
3. Wu X, Lin X, Dinney CP, Gu J, Grossman HB. Genetic polymorphism in bladder cancer. Front. Biosci. 12, 192-213 (2007).
4. Avritscher EB, Cooksley CD, Grossman HB et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 68(3), 549-553 (2006).
5. Konety BR, Joyce GF, Wise M. Bladder and upper tract urothelial cancer. J. Urol. 177(5), 1636-1645 (2007). (Pubitemid 46560679)
6. Babjuk M, Oosterlinck W, Sylvester R et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol. 54(2), 303-314 (2008). • Updated European Association of Urology (EAU) guidelines recommend fluorescence cystoscopy to assess carcinoma in situ (CIS) while performing transurethral resection of bladder tumors (TURBT).
7. Hall MC, Chang SS, Dalbagni G et al. Guideline for the management of nonmuscle invasive bladder cancer (Stages Ta, T1, and Tis): 2007 update. J. Urol. 178(6), 2314-2330 (2007). (Pubitemid 350080987)
8. Burchardt P. The flexible panendoscope. J. Urol. 127(3), 479-481 (1982).
9. Lee CS, Yoon CY, Witjes JA. The past, present and future of cystoscopy: the fusion of cystoscopy and novel imaging technology. BJU Int. 102(9 Pt B), 1228-1233 (2008).
10. van der Aa MN, Steyerberg EW, Sen EF et al. Patients' perceived burden of cystoscopic and urinary surveillance of bladder cancer: a randomized comparison. BJU Int. 101(9), 1106-1110 (2008).
11. Zippe C, Pandrangi L, Potts JM et al. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer. Anticancer Res. 19(4A), 2621-2623 (1999). (Pubitemid 29422291)
12. Smith JA, Labasky RF, Cockett ATK, Fracchia JA, Montie JE, Rowland RG. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and Tis). J. Urol. 162(5) 1697-1701 (1999)
13. SIU. International consultation on bladder tumours. Urology 66(Suppl. 6A) (2005).
14. Sternberg CN, Donat SM, Bellmunt J et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 69(Suppl. 1), 62-79 (2007). (Pubitemid 46186484)
15. Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette- Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol. 163(4), 1124-1129 (2000).
16. Au JL, Badalament RA, Wientjes MG et al. Methods to improve efficacy of intravesical mitomycin C: Results of a Randomized Phase III Trial. J. Natl Cancer Inst. 93(8), 597-604 (2001).
17. Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J. Urol. 174(1), 86-91 (2005). (Pubitemid 40825679)
18. Sonpavde G, Sternberg CN. Treatment of metastatic urothelial cancer - opportunities for drug discovery and development. BJU Int. 102(9 Pt B), 1354-1360 (2008).
19. Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a Combined Analysis of 2596 Patients from Seven EORTC Trials. Eur. Urol. 49(3), 466-1465 (2006). (Pubitemid 43259554)
20. Stenzl A, Cowan NC, De Santis M et al. The updated EAU guidelines on muscleinvasive and metastatic bladder cancer. Eur. Urol. DOI 10.1016/j.eururo.2009.01.002 (2009) (Epub ahead of print).
21. Goh AC, Lerner SP. Application of new technology in bladder cancer diagnosis and treatment. World J. Urol. 27(3), 301-307 (2009).
22. Witjes JA, Douglass J. The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer. Nat Clin. Pract. Urol. 4(10), 542-549 (2007). (Pubitemid 47554987)
23. Frampton JE, Plosker GL. Hexyl aminolevulinate: in the detection of bladder cancer. Drugs 66(4), 571-578; discussion 579-580 (2006).
24. Denzinger S, Burger M, Walter B et al. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology 69(4), 675-679 (2007). (Pubitemid 46574917)
25. Marti A, Lange N, van den Bergh H et al. Optimisation of the formation and distribution of protoporphyrin IX in the urothelium: an in vitro approach. J. Urol. 162(2), 546-552 (1999). (Pubitemid 29434395)
26. Lange N, Jichlinski P, Zellweger M et al. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study. Br. J. Cancer 80(1-2), 185-193 (1999). (Pubitemid 29210105)
27. Jichlinski P, Aymon D, Wagnieres GA et al. On the influence of the instillation time on the results of HAL (Hexvix) fluorescence detection of superficial bladder cancer. Diagnostic Optical Spectroscopy in Biomedicine II, SPIE, 5141, 272-277 (2003).
28. Marti A, Jichlinski P, Lange N et al. Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer. J. Urol. 170(2 Pt 1), 428-432 (2003). (Pubitemid 36870217)
29. Jichlinski P, Guillou L, Karlsen SJ et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer - a multicenter study. J. Urol. 170(1), 226-229 (2003). (Pubitemid 36734467)
30. Schmidbauer J, Witjes F, Schmeller N et al. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J. Urol. 171(1), 135-138 (2004). (Pubitemid 37549108)
31. Jocham D, Witjes F, Wagner S et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, Phase III multicenter study. J. Urol. 174(3), 862-866 (2005). (Pubitemid 41140613)
32. Grossman HB, Gomella L, Fradet Y et al. A Phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J. Urol. 178(1), 62-67 (2007). (Pubitemid 46908730)
33. Fradet Y, Grossman HB, Gomella L et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a Phase III, multicenter study. J. Urol. 178(1), 68-73 (2007). (Pubitemid 46908730)
34. Mynderse L, Stenzl A, Denzinger S et al. Hexvix fluorescence cystoscopy improves detection and resection of papillary bladder cancer and reduces early recurrences. J. Urol. 181(4), 689 (2009). • For the first time this prospective randomized Phase III multicenter trial demonstrates a reduced recurrence rate over a 9-month follow-up, and an improved (CIS) detection using hexaminolevulinate (HEXVIX®).
35. Zaak D, Kriegmair M, Stepp H et al. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies. Urology 57(4), 690-694 (2001).
36. Dale W, Bilir P, Han M, Meltzer D. The role of anxiety in prostate carcinoma: a structured review of the literature. Cancer 104(3), 467-478 (2005). (Pubitemid 41022802)
37. Latini DM, Hart SL, Knight SJ et al. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J. Urol. 178(3 Pt 1), 826-831; discussion 831-1822 (2007).
38. Ullrich PM, Carson MR, Lutgendorf SK, Williams RD. Cancer fear and mood disturbance after radical prostatectomy: consequences of biochemical evidence of recurrence. J. Urol. 169(4), 1449-1452 (2003).
39. Bellizzi KM, Latini DM, Cowan JE, DuChane J, Carroll PR. Fear of recurrence, symptom burden, and health-related quality of life in men with prostate cancer. Urology 72(6), 1269-1273 (2008).
40. Hart SL, Latini DM, Cowan JE, Carroll PR. Fear of recurrence, treatment satisfaction, and quality of life after radical prostatectomy for prostate cancer. Support Care Cancer 16(2), 161-169 (2008).
41. Costanzo ES, Lutgendorf SK, Mattes ML et al. Adjusting to life after treatment: distress and quality of life following treatment for breast cancer. Br. J .Cancer 97(12), 1625-1631 (2007).
42. Kornblith AB, Powell M, Regan MM et al. Long-term psychosocial adjustment of older versus younger survivors of breast and endometrial cancer. Psychooncology 16(10), 895-903 (2007). (Pubitemid 350018158)
43. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21(18), 1315-1330 (2003). (Pubitemid 37094030)
44. Sievert KD, Amend B, Nagele U et al. Economic aspects of bladder cancer: what are the benefits and costs? World J. Urol. 27(3), 295-300 (2009). • New treatment options initially provoke higher costs after the initial diagnosis. However, long-term cost benefits can be achieved through reduced tumor recurrence and potentially reduced progression rates.
45. Brausi M, Collette L, Kurth K et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur. Urol. 41(5), 523-531 (2002).
46. Brauers A, Buettner R, Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early? J. Urol. 165(3), 808-810 (2001). (Pubitemid 32156283)
47. Klan R, Loy V, Huland H. Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J. Urol. 146(2), 316-318 (1991).
48. Schwaibold HE, Sivalingam S, May F, Hartung R. The value of a second transurethral resection for T1 bladder cancer. BJU Int. 97(6), 1199-1201 (2006). (Pubitemid 43907321)
49. Divrik RT, Yildirim U, Zorlu F, Ozen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J. Urol. 175(5), 1641-1644 (2006).
50. Kriegmair M, Zaak D, Stepp H et al. Transurethral resection and surveillance of bladder cancer supported by 5-aminolevulinic acid-induced fluorescence endoscopy. Eur. Urol. 36(5), 386-392 (1999). (Pubitemid 29452707)
51. Riedl CR, Daniltchenko D, Koenig F et al. Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J. Urol. 165(4), 1121-1123 (2001). (Pubitemid 32210216)
52. Ukai R, Kawashita E, Ikeda H. A new technique for transurethral resection of superficial bladder tumor in 1 piece. J. Urol. 163(3), 878-879 (2000). (Pubitemid 30091636)
53. Saito S. Transurethral en bloc resection of bladder tumors. J. Urol. 166(6), 2148-2150 (2001). (Pubitemid 33065241)
54. D'Hallewin MA, Kamuhabwa AR, Roskams T, De Witte PA, Baert L. Hypericin-based fluorescence diagnosis of bladder carcinoma. BJU Int. 89(7), 760-763 (2002). (Pubitemid 34429548)
55. Kubin A, Meissner P, Wierrani F et al. Fluorescence diagnosis of bladder cancer with new water soluble hypericin bound to polyvinylpyrrolidone: PVP-hypericin. Photochem. Photobiol. 84(6), 1560-1563 (2008).
56. Sim HG, Lau WK, Olivo M, Tan PH, Cheng CW. Is photodynamic diagnosis using hypericin better than white-light cystoscopy for detecting superficial bladder carcinoma? BJU Int. 95(9), 1215-1218 (2005). (Pubitemid 40799433)
57. Pan Y, Xie H, Fedder GK. Endoscopic optical coherence tomography based on a microelectromechanical mirror. Opt. Lett. 26(24), 1966-1968 (2001).
58. Machida H, Sano Y, Hamamoto Y et al. Narrow-band imaging in the diagnosis of colorectal mucosal lesions: a pilot study. Endoscopy 36(12), 1094-1098 (2004). (Pubitemid 39642471)
59. Bryan RT, Billingham LJ, Wallace DM. Narrow-band imaging flexible cystoscopy in the detection of recurrent urothelial cancer of the bladder. BJU Int. 101(6), 702-705; discussion 705-706 (2008).
60. Kruck S, Horstmann M, Gakis G et al. Virtual TUR simualtor training for novice urologists - first-time transurethral resection (TUR) of the bladder. Presented ar: EAU Annual Meeting, Stockholm, Sweden 17-21 March 2009.
61. NCI SEER Stat Fact Sheets http://seer.cancer.gov/statfacts/html/urinb. html
62. American Cancer Society. Cancer Facts and Figures 2008 www.cancer.org/docroot/STT/content/STT-1x-Cancer-Facts-and-Figures-2008.asp
63. SEER Cancer Statistics Review 1975-2005 http://seer.cancer.gov/cgi-bin/ csr/1975-2005/search.pl#results
64. UroVysion bladder cancer kit www.urovysion.com/IntendedUse-357.aspx
65. NMP22® BladderChek® Test http://matritech.com/bladderchek.php
66. NCCN practice guidelines in oncology, version 1 (2007) www.nccn.org/professionals/physician-gls/PDF/bladder.pdf